p-1305
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 3, 2018 (NCT03733990)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ubiquitin-conjugating enzyme E2 TINHIBITOR
UBE2T inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05171062 | Phase 1 | Dec 31, 2022 | Faron Pharmaceuticals Ltd, University of Texas, San Antonio |
| NCT03733990 | Phase 1/Phase 2 (Phase 2) | Dec 3, 2018 | Faron Pharmaceuticals Ltd, Terveystalo Lahti |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Faron Pharmaceuticals Ltd | For profit | 2 | 1 | 2 | 2018 |
| Terveystalo Lahti | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1